ArticleCancer communications (London, England)2023

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.

Yang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.